Taking people in FranceNo phase

Growing Intestinal Mini-Organs From Patient Biopsies

Studies intestinal mini-organs grown from biopsies of adults with bowel disease.

Key facts

Who runs it: Rennes University Hospital
Where: Rennes, FranceSee the site
Trial code: NCT05294107
Registry title: Intestinal Organoids
Status: Recruiting
People taking part: 90 people, planned
Started: 6 Sept 2022
Expected to end: 7 Mar 2028
Type of study: Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested: additional biopsies
Record updated: 17 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 75 who are having a routine endoscopy and need gut biopsy samples taken. Extra biopsies are used to grow mini-organs (organoids) in the lab.

Age: 18 to 75 years
Sex: All sexes can join.
Earlier treatment: People on anticoagulant or anti-platelet treatment cannot join, except aspirin 75 mg.

Main reasons for not taking part

Under legal protection (safeguard of justice, curatorship or guardianship) or deprived of liberty
Anticoagulant treatment
Anti-platelet treatment (except aspirin 75 mg)

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

Subjects aged 18 to 75 years
Subject undergoing endoscopy as part of the standard of care with the need to take digestive biopsy samples
Subject having signed a free and informed consent in writing

Who cannot take part

Anticoagulant treatment and anti-platelet treatment (except for aspirin 75 mg)
Subjects under legal protection (safeguard of justice, curatorship or guardianship) or deprived of liberty

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 18 and 75 years old?

Where in France

CHU de RENNES-Service des Maladies de l'Appareil DigestifRennes, FranceContact: Guillaume BOUGUEN, ProfessorTaking people

About the trial

What the trial wants to find out

Over the last decade, the use of mini-organ or organoids has been increasingly developed in fundamental research. Indeed, digestive organoids represent an essential advance compared to classical culture systems (epithelial cell lines, immortalized cells) since they preserve in culture the functional complexity present in vivo (architecture, different cell types). They also have the advantage of being able to be propagated indefinitely (unlike explants), minimizing the use of animal models and reducing the amount of tissue required. Finally, their growth and development depends on the origin of the sample (the organoid will develop differently if the cell source comes from a patient suffering from an inflammatory bowel disease, for example), thus generating models of human pathologies to better determine their physiopathology. The use of organoids in biomedical research has proven to be an indispensable tool for the understanding of cellular and molecular mechanisms involved in epithelial renewal and the screening of molecules and ingredients for applications in the health and agri-food sectors.

The 3 groups in the trial

Group Crohn's diseaseTreatment being tested
4 additional biopsies for 30 patients with Crohn's disease
Treatment: additional biopsies
Group ulcerative colitisTreatment being tested
4 additional biopsies for 30 patients with ulcerative colitis
Treatment: additional biopsies
Group No MICIExisting treatment, for comparison
4 additional biopsies for 30 patients out of Inflammatory Disease Chronic Bowel Disease
Treatment: additional biopsies